Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GH/GHRH axis in HIV lipodystrophy.

Takara L Stanley1, Steven K Grinspoon

  • 1Program in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, LON5-207, 55 Fruit St., Boston, MA, 02114, USA.

Pituitary
|February 14, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pitavastatin effect on enterocyte injury markers in an ART treated HIV population: Insights from REPRIEVE.

AIDS (London, England)·2026
Same author

Primary Prevention for People Living With HIV: A Call to Action.

Journal of the American College of Cardiology·2026
Same author

Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial.

The lancet. HIV·2026
Same author

Proteomic Profile After Intervention With Eplerenone Among Persons With HIV.

Open forum infectious diseases·2026
Same author

Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis.

The lancet. HIV·2026
Same author

Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.

The lancet. HIV·2026
Same journal

Clinician decision-making in non-functioning pituitary adenomas: an Australian and New Zealand interdisciplinary survey study.

Pituitary·2026
Same journal

Does persistent hyperprolactinemia contribute to bone loss independently of estrogen deficiency in postmenopausal women?

Pituitary·2026
Same journal

Gauze swabbing technique for safe dissection of pituitary tumors.

Pituitary·2026
Same journal

Postoperative changes in circulating brain injury biomarkers in relation to long-term fatigue and cognitive outcomes after surgery for nonfunctioning pituitary adenomas.

Pituitary·2026
Same journal

Pituitary metastasis as an endocrine-neuro-ophthalmologic emergency: clinical red flags and outcomes from a contemporary tertiary-center series.

Pituitary·2026
Same journal

GH responsiveness to corticotropin-releasing hormone identifies corticotroph-like somatotroph adenomas in acromegaly.

Pituitary·2026
See all related articles

Antiretroviral therapy for HIV can cause lipodystrophy, affecting body fat and increasing cardiovascular risk. Growth hormone therapy can help manage these metabolic changes and improve body composition in patients with HIV.

Area of Science:

  • Endocrinology
  • Infectious Diseases
  • Metabolic Disorders

Background:

  • Antiretroviral therapy (ART) in HIV patients is linked to abnormal body fat distribution (lipodystrophy).
  • HIV lipodystrophy is associated with dyslipidemia, insulin resistance, and increased cardiovascular risk.
  • Patients with HIV lipodystrophy exhibit reduced growth hormone (GH) secretion, characterized by decreased pulse amplitude and width.

Purpose of the Study:

  • To investigate the association between GH secretion abnormalities and metabolic/body composition changes in HIV lipodystrophy.
  • To evaluate the efficacy and safety of GH or growth hormone-releasing hormone (GHRH) administration for treating HIV lipodystrophy.

Main Methods:

  • Assessed GH secretion patterns (pulse frequency, amplitude, width, trough levels) in HIV patients compared to controls.

Related Experiment Videos

  • Correlated GH secretion abnormalities with body composition (visceral fat) and metabolic parameters (lipids, insulin resistance).
  • Reviewed studies on the effects of exogenous GH and GHRH administration in HIV-infected patients.

    • Main Results:

    • Abnormal GH secretion (normal pulse frequency, decreased amplitude/width, lower trough levels) is strongly linked to visceral fat and elevated free fatty acids in HIV lipodystrophy.
    • Exogenous GH or GHRH administration effectively reduces visceral fat and improves lipid profiles.
    • Physiologic GH doses show modest effects with fewer side effects compared to supraphysiologic doses.
    • GHRH demonstrates potential for normalizing GH dynamics with fewer adverse effects than GH.

    Conclusions:

    • Abnormal growth hormone secretion contributes significantly to metabolic and body composition abnormalities in HIV lipodystrophy.
    • Growth hormone-releasing hormone (GHRH) offers a promising therapeutic strategy for managing HIV lipodystrophy by normalizing endogenous GH secretion.
    • GHRH may improve visceral adipose tissue and lipid parameters with a favorable safety profile.